



ÇOCUKLARDA MULTİSİSTEM İNFLAMATUVAR SENDROM (MIS-C)

Prof. Dr. Ergin ÇİFTÇİ

Ankara Üniversitesi Tıp Fakültesi
Çocuk Enfeksiyon Hastalıkları Bilim Dalı

www.erginciftci.com



COVID-19 and Kawasaki Disease: Novel Virus and Novel Case

DOI: 10.1542/hpeds.2020-0123

Journal: *Hospital Pediatrics*



Figure 3. Upper extremity erythema and edema. Image shared with parental permission.

KAWASAKİ HASTALIĞI

Halk Diliyle Anlatabilmek...




TOMİSAKU KAWASAKİ

Gizemli Hastalığın İsim Babası



TOMİSAKU KAWASAKİ

Gizemli Hastalığın İsim Babası



Çocuklarda
Multisistem İnflamatuvar Sendrom (MIS-C)

KAWASAKİ HASTALIĞI

Kısa Tarihçe

Pediatr Infect Dis J, 2002;21:993-5
Copyright © 2002 by Lippincott Williams & Wilkins, Inc.


Commentary: Translation of Dr. Tomisaku Kawasaki's original report of fifty patients in 1967

JANE C. BURNS, MD

The description in Japanese by Tomisaku Kawasaki of 50 infants and children suffering from a curious new ailment in Japan in the 1960s has now been translated into English and is available for readers at <http://www.pidj.com>. It is truly a masterpiece of descriptive clinical writing from the past century.¹ In his exhaustive detailing of every observable aspect of the disease, Kawasaki was part Sherlock Holmes and part Charles Dickens with his sense of mystery and his vivid descriptions of the clinical features of these patients. So careful are the daily observations of his patients that when one reads in the detailed description of the first case that the patient “smiled for the first time” on the 26th day of his illness, one is convinced that this is an accurate statement.

KAWASAKİ HASTALIĞI

Kısa Tarihçe



KAWASAKİ HASTALIĞI

Klinik Bulgular



Classic KD is diagnosed in the presence of fever for at least 5 d (the day of fever onset is taken to be the first day of fever) together with at least 4 of the 5 following principal clinical features. In the presence of ≥ 4 principal clinical features, particularly when redness and swelling of the hands and feet are present, the diagnosis of KD can be made with 4 d of fever, although experienced clinicians who have treated many patients with KD may establish the diagnosis with 3 d of fever in rare cases (Figure 2):

1. Erythema and cracking of lips, strawberry tongue, and/or erythema of oral and pharyngeal mucosa
2. Bilateral bulbar conjunctival injection without exudate
3. Rash: maculopapular, diffuse erythroderma, or erythema multiforme-like
4. Erythema and edema of the hands and feet in acute phase and/or periungual desquamation in subacute phase
5. Cervical lymphadenopathy (≥ 1.5 cm diameter), usually unilateral

KAWASAKİ HASTALIĞI

Klinik Bulgular

ATEŞ

**Klasik Kawasaki tanısı en az 5 gün ateşe dayanır.
Tipik bulgular varsa 4 veya 3 gün süren ateş ile tanı konulabilir.
Ateş remittan tiptedir ($>39-40^{\circ}\text{C}$)
Uygun tedavi verilmezse 1-3 hafta boyunca sürer.
Kendiliğinden 7 günde düşen ateş tanıyı dışlamaz.
Ateş genellikle IVIG infüzyonunu takiben 36 saat içinde düşer.**

KAWASAKİ HASTALIĞI

Klinik Bulgular

Incomplete Kawasaki disease in an infant presenting with only prolonged fever

Halil Özdemir¹, Aylin Çiftçi², Adem Karbuz¹, Ergin Çiftçi¹, Ercan Tutar³, Semra Atalay³, Erdal İnce¹



Fig. 1. Echocardiogram showing saccular aneurysm of the right coronary artery (3.5 mm in width).



Fig. 2. A fusiform aneurysm of the left coronary artery (4.5 mm in width and 8 mm in length).

A 2.5-month-old boy admitted to our hospital with irritability, poor feeding and fever of 12 hours' duration. On physical examination, he was febrile and extremely irritable. Initial whole blood count revealed a hemoglobin level of 10.1 g/dl, white blood count of 17,800/mm³ and platelet count of 454,000/mm³. Erythrocyte sedimentation rate was 80 mm/h and C-reactive protein was 3.96 mg/dl. Biochemical examinations of serum, urinalysis, chest X-ray, and analysis of cerebrospinal fluid (CSF) were normal. He was started on intravenous ampicillin and ceftriaxone empirically for provisional occult bacteremia. His blood, urine and CSF cultures were negative. On the 7th day of the treatment, there were no additional symptoms or findings other than fever. Echocardiography revealed aneurysms in both the left and right coronary arteries. Intravenous immunoglobulin (IVIG) and per oral aspirin were administered, and the fever resolved after IVIG infusion. Two years later, the echocardiography showed disappearing of the saccular aneurysm on the right coronary artery, but the dilatation of the left coronary artery was persisting. In conclusion, incomplete Kawasaki disease should always be included in the differential diagnosis of an infant with persistent fever, especially one younger than three months of age, when the conventional fails to reveal the underlying cause.

KAWASAKİ HASTALIĞI

Klinik Bulgular

KAWASAKI DISEASE WITHOUT FEVER

Claas H. Hinze, MD, Thomas B. Graham, MD,*
and Jamie S. Sutherell, MD†*

Abstract: Kawasaki disease (KD) characteristically presents with prolonged, remittent fever in addition to other clinical findings. We report the case of a 3-month-old boy who developed characteristic manifestations of KD and coronary aneurysms in the absence of fever. This case report underlines the difficulty to diagnose KD in young infants.

Kawasaki Disease Without Fever: A Mild Disease?

*Gámez-González Luisa Berenise¹, Rivera-Rodriguez Leonardo², García-Pavón Susana³,
Rivas-Larrauri Francisco⁴, Yamazaki-Nakashimada Marco²⁻⁴*

Results: Although rare, KD can occasionally present without fever. A total of eleven cases of non-fever KD have been described. The majority of cases do not present major complications. Conclusion:

Classic KD is diagnosed in the presence of fever for at least 5 d (the day of fever onset is taken to be the first day of fever) together with at least 4 of the 5 following principal clinical features. In the presence of ≥ 4 principal clinical features, particularly when redness and swelling of the hands and feet are present, the diagnosis of KD can be made with 4 d of fever, although experienced clinicians who have treated many patients with KD may establish the diagnosis with 3 d of fever in rare cases (Figure 2):

1. Erythema and cracking of lips, strawberry tongue, and/or erythema of oral and pharyngeal mucosa
2. Bilateral bulbar conjunctival injection without exudate
3. Rash: maculopapular, diffuse erythroderma, or erythema multiforme-like
4. Erythema and edema of the hands and feet in acute phase and/or periungual desquamation in subacute phase
5. Cervical lymphadenopathy (≥ 1.5 cm diameter), usually unilateral

KAWASAKİ HASTALIĞI

Klinik Bulgular

DÖKÜNTÜ

Döküntü genellikle ilk 5 gün içinde ortaya çıkar.

En sık yaygın makülopapüler döküntü görülür

Scarlatiniform eritroderma

Eritema multiforme

Nadiren ürtikeryal veya mikropüstüler döküntü görülebilir

Büllöz, veziküler ve peteşial döküntü beklenmez

Döküntü, öncelikle gövde ve ekstremitelerdedir.

Kasık bölgesinde daha belirgin olup daha erken soyulur.

KAWASAKİ HASTALIĞI

Klinik Bulgular



KAWASAKİ HASTALIĞI

Klinik Bulgular



KAWASAKİ HASTALIĞI

Klinik Bulgular

EKSTREMİTE DEĞİŞİKLİKLERİ

Ekstremitelerdeki değişiklikler en belirgin bulgulardandır.

Avuç içi ve ayak tabanları kızarıklık, el ve ayakta bazen ağrılı olan endurasyon görülür.

Ateş başlangıcından sonra 2-3 hafta içinde el ve ayak parmaklarından başlayan soyulma görülür.

Ateş başlangıcından 1-2 ay sonra, tırnaklarda derin transvers oluklar (**Beau çizgileri**) görülebilir.



KAWASAKİ HASTALIĞI

Klinik Bulgular



KAWASAKİ HASTALIĞI

Klinik Bulgular



KAWASAKİ HASTALIĞI

Klinik Bulgular

KONJONKTİVAL KIZARIKLIK

Ateş başladıktan kısa bir süre sonra başlar.

Bilateral bulbar eksudatif olmayan konjonktival kızarıklık görülür.

Sıklıkla iris çevresindeki avasküler limbus bölgesini tutmaz.

Ön üveit (yarık lamba muayenesinde) ateşin ilk haftasında sıktır.

Subkonjonktival kanama ve punktat keratit bazen görülür.

KAWASAKİ HASTALIĞI

Klinik Bulgular



KAWASAKİ HASTALIĞI

Klinik Bulgular

AĞIZ DEĞİŞİKLİKLERİ

- (1) Dudaklarda eritem, kuruluk, çatlama, soyulma ve kanama
- (2) Çilek dili: dilde kızarıklık ve fungiform papillar belirgin
- (3) Orofaringeal mukozada yaygın kızarıklık

Oral ülserler ve faringeal eksüdalar beklenmez.

KAWASAKİ HASTALIĞI

Klinik Bulgular



KAWASAKİ HASTALIĞI

Klinik Bulgular

SERVİKAL LENFADENOPATİ

Servikal lenfadenopati en az görülen tanı kriteridir.

Genellikle tek taraflı ≥ 1.5 cm çapında, ön servikal üçgen ile sınırlı.

Bazen lenf bezi bulguları en belirgin bulgu olabilir.

Bakteriyel lenfadenit düşündürür

Antibiyotiğe rağmen ateş devam eder

Döküntü ve konjonktival kızarıklık gibi diğer bulgular izler

USG ve BT tanıda yardımcı olabilir

KAWASAKİ HASTALIĞI

Klinik Bulgular




Çocuklarda
Multisistem İnflamatuvar Sendrom (MIS-C)

Ankara Üniversitesi Tıp Fakültesi
Çocuk Enfeksiyon Hastalıkları Arşivi


KAWASAKİ HASTALIĞI

Klinik Bulgular




KAWASAKİ HASTALIĞI

Klinik Bulgular



KAWASAKİ HASTALIĞI

Klinik Bulgular



KAWASAKİ HASTALIĞI

Klinik Bulgular



KAWASAKİ HASTALIĞI

Klinik Bulgular

Kawasaki Sendromuna Bağlı Dev Koroner Anevrizma

Ömer Çiftçi¹, Cem Karadeniz¹, Bilge Aldemir Kocabaş², Adem Karbuz², Tayfun Uçar¹, Erdal İnce², Ercan Tutar¹, Ergin Çiftçi², Semra Atalay¹

ONSEKİZ YILLIK KAWASAKİ HASTALIĞI DENEYİMİMİZ: NADİR SEMPTOM VE BULGULARLA HASTALIĞIN DİĞER YÜZÜ

Bilge Aldemir Kocabaş¹, Adem Karbuz¹, Cem Karadeniz², Ömer Çiftçi², Halil Özdemir¹, Gökalep Musa Bolkent³, Tayfun Uçar², Ercan Tutar², Semra Atalay², Suat Fitöz⁴, Ergin Çiftçi¹, Erdal İnce¹



KAWASAKİ HASTALIĞI

Klinik Bulgular

Nervous system
Extreme irritability
Aseptic meningitis (pleocytosis of cerebrospinal fluid)
Facial nerve palsy
Sensorineural hearing loss
Genitourinary
Urethritis/meatitis, hydrocele
Other
Desquamating rash in groin
Retropharyngeal phlegmon
Anterior uveitis by slit lamp examination
Erythema and induration at BCG inoculation site

Other clinical findings may include the following:
Cardiovascular
Myocarditis, pericarditis, valvular regurgitation, shock
Coronary artery abnormalities
Aneurysms of medium-sized noncoronary arteries
Peripheral gangrene
Aortic root enlargement
Respiratory
Peribronchial and interstitial infiltrates on CXR
Pulmonary nodules
Musculoskeletal
Arthritis, arthralgia (pleocytosis of synovial fluid)
Gastrointestinal
Diarrhea, vomiting, abdominal pain
Hepatitis, jaundice
Gallbladder hydrops
Pancreatitis

KAWASAKİ HASTALIĞI

Laboratuvar Bulguları

Lökositoz

Nötrofil hakimiyeti

C-reaktif protein artışı

Eritrosit sedimentasyon hızı yüksekliği

Hemoglobin düşüklüğü

Sodyum düşüklüğü

Albümin düşüklüğü

Karaciğer enzimlerinde yükselme

Bilirübin yüksekliği

Steril piyüri

Trombositoz Ateş başlangıcından sonraki ikinci haftada

KAWASAKİ HASTALIĞI

Ayırıcı Tanı



Çocuklarda
Multisistem İnflamatuvar Sendrom (MIS-C)

KAWASAKİ HASTALIĞI

Ayırıcı Tanı

Solunum sinsityal virüsü

Metapneumovirüs

Coronavirüs

İnfluenza virüs

Parainfluenza virüs

...

Klinik bulguları klasik Kawasaki hastalığı ile uyumlu olan bir çocukta tanıyı dışlamaz.

Adenovirüs

KAWASAKİ HASTALIĞI

Tedavi

IVIG

2 g/kg, 10-12 saat infüzyon

Asetil salisilik asit

80-10 mg/kg/gün

30-50 mg/kg/gün

Ateş 48-72 saat düşene kadar veya 14 gün

3-5 mg/kg/gün, 6-8 hafta

KAWASAKİ HASTALIĞI

IVIG Dirençli Vakalarda Tedavi

Agent	Description	Dose
Most frequently administered		
IVIG: Second infusion	Pooled polyclonal IG	2 g/kg IV
IVIG + prednisolone	IVIG + steroid	IVIG: 2 g/kg IV + prednisolone 2 mg·kg ⁻¹ ·d ⁻¹ IV divided every 8 h until afebrile, then prednisone orally until CRP normalized, then taper over 2–3 wk
Infliximab	Monoclonal antibody against TNF- α	Single infusion: 5 mg/kg IV given over 2 h
Alternative treatments		
Cyclosporine	Inhibitor of calcineurin-NFAT pathway	IV: 3 mg·kg ⁻¹ ·d ⁻¹ divided every 12 h PO: 4–8 mg·kg ⁻¹ ·d ⁻¹ divided every 12 h Adjust dose to achieve trough 50–150 ng/mL; 2-h peak level 300–600 ng/mL
Anakinra	Recombinant IL-1 β receptor antagonist	2–6 mg·kg ⁻¹ ·d ⁻¹ given by subcutaneous injection
Cyclophosphamide	Alkylating agent blocks DNA replication	2 mg·kg ⁻¹ ·d ⁻¹ IV
Plasma exchange	Replaces plasma with albumin	Not applicable

IVIG resistance is defined as persistent or recrudescence fever at least 36 hours and <7 days after completion of first IVIG infusion.

KAWASAKİ HASTALIĞI

Tomisaku Kawasaki

It was in January 1961 that I encountered a child patient, aged 4 years and 3 months, who was to become the first known case of Kawasaki disease. Fifty years have elapsed since then. At the time, I had no choice but to discharge the patient as "diagnosis unknown." Fortunately, the child suffered no sequelae, and is currently enjoying a full and active life as an adult. Since then the incidence of Kawasaki disease has continued to grow. Why? Why can't we stop this disease? The reason, unfortunately, is that its cause is not known. At the time I first described the disease, I felt that we were on the threshold of discovering its cause, since its symptoms were extremely clear-cut. Despite the efforts of numerous researchers, however, we are still searching. It is my strong hope that young researchers will be able to identify the root cause of this disease.

Tomisaku Kawasaki



KAWASAKİ HASTALIĞI

Tomisaku Kawasaki

In the 2012 interview, Dr. Kawasaki speculated on why distinct cases of the new disease began to emerge in the 1960s. “Probably the use of measles vaccine made it easier to recognize cases of this new entity,” he said, “because measles cases became less common in the population.”

Dr. Tomisaku Kawasaki, Who Pinpointed a Mysterious Disease, Dies at 95

In 1967, he identified a disease that causes heart inflammation in children, one that Covid-19 has brought back into the news.



Dr. Tomisaku Kawasaki in an undated photo. He identified a multisymptom inflammatory syndrome among children that some researchers thought may have been linked to exposure to the new coronavirus. Agence France-Presse — Getty Images

By Neil Genzlinger

June 17, 2020



Dr. Tomisaku Kawasaki, who in 1967 first identified a disease in children that remains mysterious today and that has recently been in the news in relation to Covid-19, died on June 5 in Tokyo. He was 95.



COVID-19

Yeni Ortaya Çıkan Enfeksiyon Hastalığı



COVID-19

Yeni Ortaya Çıkan Enfeksiyon Hastalığı



SARA GIRONI CARNEVALE

Scientists are drowning in COVID-19 papers. Can new tools keep them afloat?

By Jeffrey Brainard | May. 13, 2020 , 12:15 PM

Science's COVID-19 reporting is supported by the Pulitzer Center.

Timothy Sheahan, a virologist studying COVID-19, wishes he could keep pace with the growing torrent of new scientific papers about the disease and the novel coronavirus that causes it. But there are just too many—more than 4000 alone last week. “I’m not keeping up,” says Sheahan, who works at the University of North Carolina, Chapel Hill. “It’s impossible.”

COVID-19

Yeni Ortaya Çıkan Enfeksiyon Hastalığı

Why is COVID-19 so mild in children?

COVID-19 in Newborns and Infants—Low Risk of Severe Disease: Silver Lining or Dark Cloud?

Additional hypotheses about why COVID-19 is milder in children than adults

The immune system of children: the key to understanding SARS-CoV-2 susceptibility?

COVID-19

Yeni Ortaya Çıkan Enfeksiyon Hastalığı



COVID-19



MIS-C

MIS-C

Ortaya Çıkışı

Nisan 2020'de İngiltere'de ve Avrupa'da yeni enfeksiyon hastalığı

Ateş

İnflamasyon

Gastrointestinal belirtiler

Multiorgan tutulumu

Kardiyak disfonksiyon, inotrop ihtiyacı

İtalya'da Kawasaki hastalığı tanısında 30 kat artış



MULTISYMPPTOM INFLAMMATORY SYNDROME IN CHILDREN

Prof. Dr. Ergin ÇİFTÇİ
www.erginciftci.com

- FEVER
- LAB EVIDENCE OF INFLAMMATION
- HOSPITALIZATION
- INVOLVEMENT OF MORE THAN 2 ORGAN SYSTEMS
- NO OTHER POSSIBLE DIAGNOSIS

Table 3. CDC Case Definition for MIS-C

Criteria

- An individual aged < 21 years presenting with fever^a, laboratory evidence of inflammation^b, and evidence of clinically severe illness requiring hospitalization, with multisystem (≥ 2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurological); **AND**
- No alternative plausible diagnoses; **AND**
- Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms

^aFever > 38.0°C for ≥ 24 hours, or report of subjective fever lasting ≥ 24 hours

^bIncluding, but not limited to, 1 or more of the following: an elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, D-dimer, ferritin, lactic acid dehydrogenase (LDH), or interleukin 6 (IL-6), elevated neutrophils, reduced lymphocytes, and low albumin

MIS-C

**Çocuklarda
Multisistem İnflamatuvar Sendrom (MIS-C)**

Box. WHO Criteria for MIS-C^a

Children and adolescents 0 to 19 years old with fever >3 days

AND 2 of the following:

Rash or bilateral nonpurulent conjunctivitis or mucocutaneous inflammation signs (oral, hands, or feet)

Hypotension or shock

Features of myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities (including echocardiographic findings or elevated troponin/NT-proBNP)

Evidence of coagulopathy (by prothrombin time, partial thromboplastin time, elevated D-dimer levels)

Acute gastrointestinal symptoms (diarrhea, vomiting, or abdominal pain)

AND elevated markers of inflammation such as erythrocyte sedimentation rate, C-reactive protein level, or procalcitonin level

AND no other obvious microbial cause of inflammation, including bacterial sepsis, staphylococcal, or streptococcal shock syndromes

AND evidence of COVID-19 (RT-PCR, antigen test, or serology positive) or likely contact with patients with COVID-19

Abbreviations: COVID-19, coronavirus disease 2019; MIS-C, multisystem inflammatory syndrome in children; NT-proBNP, N-terminal pro-brain natriuretic peptide; RT-PCR, reverse transcriptase-polymerase chain reaction; WHO, World Health Organization.

^a Based on WHO criteria.¹⁸



MIS-C

MIS-C

Patogenezi

Neden geliştiği belirsiz...


SARS-CoV-2 virüs replikasyonunun doğrudan etkisi
Post-enfeksiyöz immün disregülasyon
Her iki durumun birlikteliği

Post-enfeksiyöz olma olasılığı daha yüksek görülüyor.

İmmün modulator antiinflamatuvar tedaviye yanıt
Anti-viral tedavi olmadan iyileşme
Enfeksiyondan 4-6 hafta sonra görülmesi
IgG üretiminin IgM'yi geçtiği dönemde görülmesi
Çoğu hastada SARS-CoV-2 antikor pozitifliği
NP viral yükün şiddetli COVID-19'a göre daha düşük olması

MIS-C

COVID-19 Nerede Başlıyor Nerede Bitiyor?



	Asymptomatic or Presymptomatic	Mild Illness	Moderate Illness	Severe Illness	Critical Illness
Features	Positive SARS-CoV-2 test; no symptoms	Mild symptoms (e.g., fever, cough, or change in taste or smell); no dyspnea	Clinical or radiographic evidence of lower respiratory tract disease; oxygen saturation $\geq 94\%$	Oxygen saturation $< 94\%$; respiratory rate ≥ 30 breaths/min; lung infiltrates $> 50\%$	Respiratory failure, shock, and multiorgan dysfunction or failure
Testing	Screening testing; if patient has known exposure, diagnostic testing	Diagnostic testing	Diagnostic testing	Diagnostic testing	Diagnostic testing
Isolation	Yes	Yes	Yes	Yes	Yes
Proposed Disease Pathogenesis					
Potential Treatment					
Management Considerations	Monitoring for symptoms	Clinical monitoring and supportive care	Clinical monitoring; if patient is hospitalized and at high risk for deterioration, possibly remdesivir	Hospitalization, oxygen therapy, and specific therapy (remdesivir, dexamethasone)	Critical care and specific therapy (dexamethasone, possibly remdesivir)


Multisystem Inflammatory Syndrome in U.S. Children and Adolescents



This article was published on June 29, 2020, at NEJM.org.

Çocuk hasta sayısı	186
Median yaş	8.3 yıl
Mortalite	%2
Koroner arter anevrizması	%8
Vazoaktif destek	%48

Temporal Relationship between MIS-C and Covid-19 Activity in Persons <21 Yr of Age




Multisystem Inflammatory Syndrome in Children in New York State



This article was published on June 29, 2020, at NEJM.org.

Çocuk hasta sayısı 95
0-5 Yaş %31 6-12 Yaş %42 13-20 Yaş %26
Mortalite %2
Koroner arter anevrizması %9
Vazoaktif destek %61



MIS-C

Demografik Özellikler

Daha büyük yaştaki çocuklar (median yaş en az 8 yıl, Kawasaki 2 yıl)

Batıda sık, Kore'de nadir, Çin ve Japonya'da neredeyse yok

Erkeklerde daha sık

Obezite en önemli eşlik eden durum

CDC

Yaş:

- ☐ <21 yaş

Ateş:

- ☐ ≥ 24 saat $> 38.0^{\circ}\text{C}$ veya
- ☐ ≥ 24 saat süren subjektif ateş

Enflamasyonun laboratuvar kanıtı:

- ☐ CRP $\uparrow$, ESR $\uparrow$, Fibrinojen $\uparrow$, Prokalsitonin $\uparrow$, D-dimer $\uparrow$, Ferritin $\uparrow$, LDH $\uparrow$, IL-6 $\uparrow$, Nötrofili, Lenfositopeni, Hipoalbuminemi

Multi organ tutulumu : ≥ 2 organ sistemi:

- ☐ KVS: Şok, troponin $\uparrow$, BNP $\uparrow$, anormal EKO, aritmi
 - ☐ SS: Pnömoni, ARDS, pulmoner emboli
 - ☐ Nefrolojik: ABY
 - ☐ SSS: Nöbet, aseptik menenjit, SVO
 - ☐ Hematolojik: Koagülopati
 - ☐ GİS: Karın ağrısı, kusma, ishal, KCFT $\uparrow$, ileus, kanama
 - ☐ Dermatolojik: Eritrodermi, mukozit, diğer döküntüler
- Hospitalizasyon gerektiren ciddi hastalık

SARS-CoV-2 enfeksiyonu veya teması:

- ☐ SARS-CoV-2 RT-PCR +
- ☐ Seroloji +
- ☐ Antijen testi +
- ☐ Semptomların başlamasından önceki 4 haftada COVID-19 teması

Alternatif tanı olmaması

WHO

Yaş:

- ☐ 0-19 yaş

Ateş:

- ☐ 3 gün ve üzeri süren ateş

Artmış inflamasyon yanıtı (ESR, CRP veya prokalsitonin)

Multi organ tutulumu: ≥ 2

- ☐ Döküntü, bilateral nonpürülan konjunktivit veya mukokutanöz inflamasyon (ağız, el/ayaklar)
- ☐ Hipotansiyon veya şok
- ☐ Kardiyak disfonksiyon, perikardit, valvülit veya koroner anormallikler (EKO veya troponin / BNP $\uparrow$)
- ☐ Koagülopati varlığı (uzamış PT veya PTT; yüksek D-dimer)
- ☐ Akut GİS semptomlar (ishal, kusma veya karın ağrısı)

SARS-CoV-2 enfeksiyonunun kanıtı:


Herhangi biri:

- ☐ SARS-CoV-2 RT-PCR +
- ☐ Seroloji +
- ☐ Antijen testi +
- ☐ COVID-19 olan bir kişiyle temas

Bakteriyel sepsis ve stafilokok/streptokok toksik şok sendromları dahil başka mikrobiyal enflamasyon nedeni olmaması

Multisystem Inflammatory Syndrome in Children (MIS-C)

Lab evidence of current or past infection with SARS-CoV-2



 Fever,
Myalgia

Conjunctivitis
Rash, Lymphadenopathy, Stomatitis,
Extremity swelling with erythema
Skin peeling

 Headache
Meningismus
Lethargy

 High ESR, CRP, ferritin,
LDH, IL-6, Fibrinogen,
Procalcitonin, CPK,
D-dimers etc.,



 Myocarditis, ↑Troponin, ↑pro-BNP
Coronary aneurysms, Hypotension
Hypoperfusion, Tachycardia

 Hypoxemia
Pulmonary infiltrates
Chest pain

 Nausea
Vomiting
Abd pain
Diarrhea
↑AST/ALT

Thrombocytopenia
Neutrophilia
Lymphopenia

 Hyponatremia
Renal failure



MIS-C

Tanı

REVIEW



Multisystem inflammatory syndrome in children

Vijaya L. Soma^a, Gail F. Shust^a, and Adam J. Ratner^{a,b}

Table 1. Reported clinical and laboratory findings in MIS-C

Fever $\geq 38.0^{\circ}\text{C}$ for ≥ 24 h with multisystem (≥ 2) organ involvement

MIS-C

Tanı

REVIEW



Multisystem inflammatory syndrome in children

Vijaya L. Soma^a, Gail F. Shust^a, and Adam J. Ratner^{a,b}

Table 1. Reported clinical and laboratory findings in MIS-C

Fever $\geq 38.0^{\circ}\text{C}$ for ≥ 24 h with multisystem (≥ 2) organ involvement

Positive SARS-CoV-2 PCR or serology OR epidemiologic link to a patient with COVID-19

MIS-C Tanı

American Academy
of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN®

Multisystem Inflammatory Syndrome in Children (MIS-C) Interim Guidance

[Critical Updates on COVID-19](#) / [Clinical Guidance](#) / Multisystem Inflammatory Syndrome in Children (MIS-C) Interim Guidance



What is the case definition of multisystem inflammatory syndrome in children (MIS-C)?

The CDC issued a [Health Advisory](#) on May 14, 2020, that outlines the following case definition for MIS-C:

- An individual aged <21 years presenting with fever,¹ laboratory evidence of inflammation,² and evidence of clinically severe illness requiring hospitalization, with multisystem (≥2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurological); **AND**
- No alternative plausible diagnoses; **AND**
- Positive for current or recent SARS-CoV-2 (COVID-19) infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms.

MIS-C

Tanı

REVIEW



Multisystem inflammatory syndrome in children

Vijaya L. Soma^a, Gail F. Shust^a, and Adam J. Ratner^{a,b}

Table 1. Reported clinical and laboratory findings in MIS-C

Fever $\geq 38.0^{\circ}\text{C}$ for ≥ 24 h with multisystem (≥ 2) organ involvement

Positive SARS-CoV-2 PCR or serology OR epidemiologic link to a patient with COVID-19

Gastrointestinal

Abdominal pain
Nausea/Vomiting
Diarrhea

Cardiovascular

Shock
Hypotension
Congestive heart failure
Myocarditis
Coronary artery dilation/aneurysm
Pericardial effusion
Valvular dysfunction
Elevated troponin
Elevated BNP¹ or NT-proBNP²



Multisystem Inflammatory Syndrome in Children (MIS-C) with COVID-19

COVID-19 ilişkili Çocuklarda Multisistem İnflamatuvar Sendromu (MIS-C)

Ergin Çiftçi¹, Gül Arga¹, Esra Çakmak Taşkın¹, Hatice Kübra Konca¹, Halil Özdemir¹

¹ Division of Pediatric Infectious Diseases, Department of Pediatrics, Ankara University School of Medicine, Ankara, Turkey

Cite this article as: Çiftçi E, Arga G, Çakmak Taşkın E, Konca HK, Özdemir H. Multisystem inflammatory syndrome in children (MIS-C) with COVID-19. J Pediatr Inf 2020;14(4):e???-e???

A seven-year-old girl was brought with complaints of fever, abdominal pain and rash. She was referred to our hospital with acute appendicitis by the hospital she first applied to. It was learned that the girl's grandfather had COVID-19 a month ago. In the examination of the patient, fever was measured as 38.5°C, redness was seen in both conjunctiva and erythema which was more prominent on the cheeks was found on the face. She had cracking and peeling on her lips, a red strawberry tongue appearance, and widespread erythema on her trunk. There was tenderness in the left lower quadrant of the abdomen. Laboratory findings were WBC: 8920/mm³, Hb: 11.6 g/dL, PLT: 50.000/mm³, CRP: 93.4 g/L, D-dimer: 8671 ng/mL, ferritin: 289 ng/mL, and albumin: 2.71 g/L. The patient's SARS-CoV-2 PCR was negative, but SARS-CoV-2 antibody was found to be positive. Echocardiography was found to be normal. Multisystem inflammatory syndrome in children (MIS-C) with COVID-19 was considered. The patient received IVIG 2 g/kg as a single dose. Prednisolone 2 mg/kg/d, aspirin 3.5 mg/kg/d, pantoprazole and piperacillin-tazobactam were also started. The patient's fever resolved; all clinical signs regressed. The antibiotic therapy was stopped on the seventh day of her hospitalization, and the patient was discharged with prednisolone tapering in 3 weeks.

Children can usually survive COVID-19 disease without any problems. On the other hand, MIS-C can be seen in some children after infection. Although it was initially thought to have characteristics similar to Kawasaki disease and toxic shock syndromes, it is now accepted as a distinct entity. MIS-C is thought to be an immunological reaction as it occurs weeks

after SARS-CoV-2 infection. MIS-C manifests itself in a patient with SARS-CoV-2 exposure history, PCR, antigen or antibody positivity, who has fever, elevated inflammatory markers, and involvement of at least two organ systems (heart, lung, kidney, skin, hematological, gastrointestinal and neurological). However, diseases that may cause a similar clinical picture in patients should be excluded. The disease can be fatal if not recognized and treated appropriately. The prognosis is generally good with IVIG and corticosteroid doses depending on the severity of the disease.



Correspondence Address/Yazışma Adresi

Ergin Çiftçi

Ankara Üniversitesi Tıp Fakültesi,
Çocuk Sağlığı ve Hastalıkları Anabilim Dalı,
Çocuk Enfeksiyon Hastalıkları Bilim Dalı,
Ankara-Türkiye

erginciftci@gmail.com

1-2020

Available Online Date: 7.7.2020

©Copyright 2020 by Pediatric Infectious Diseases and Immunization Society.
Available online at www.cocukenfeksiyon.org

MIS-C

Tanı

REVIEW



Multisystem inflammatory syndrome in children

Vijaya L. Soma^a, Gail F. Shust^a, and Adam J. Ratner^{a,b}

Dermatologic

Rash
Mucocutaneous lesions
Conjunctival injection
Periorbital edema
Swollen hands or feet

Hematologic

Elevated D-dimer
Thrombocytopenia
Lymphopenia

Respiratory

UPPER:
Sore throat
Congestion
LOWER:
Cough
Shortness of breath
Chest tightness/pain
Pneumonia
Pleural effusion
ARDS³

MIS-C

Tanı

REVIEW



Multisystem inflammatory syndrome in children

Vijaya L. Soma^a, Gail F. Shust^a, and Adam J. Ratner^{a,b}

Neurologic

Headache

Altered mental status/confusion

Renal

Acute kidney injury

Systemic inflammation

Fatigue

Weakness

Lymphadenopathy

Myalgias

Elevated CRP⁴, ESR⁵, fibrinogen, procalcitonin, LDH⁶, IL-6⁷

Decreased albumin

1. B-type natriuretic peptide; 2. N-terminal (NT)-pro hormone BNP; 3. Acute respiratory distress syndrome; 4. C-reactive protein; 5. Erythrocyte sedimentation rate; 6. Lactate dehydrogenase; 7. Interleukin-6.

MIS-C Tanı

American Academy
of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN®

Multisystem Inflammatory Syndrome in Children (MIS-C) Interim Guidance

[Critical Updates on COVID-19](#) / [Clinical Guidance](#) / Multisystem Inflammatory Syndrome in Children (MIS-C) Interim Guidance



What is the case definition of multisystem inflammatory syndrome in children (MIS-C)?

The CDC issued a [Health Advisory](#) on May 14, 2020, that outlines the following case definition for MIS-C:

- An individual aged <21 years presenting with fever,¹ laboratory evidence of inflammation,² and evidence of clinically severe illness requiring hospitalization, with multisystem (≥2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurological); **AND**
- No alternative plausible diagnoses; **AND**
- Positive for current or recent SARS-CoV-2 (COVID-19) infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms.

Çocuklarda Görülen COVID-19 İlişkili Multisistem İnflamatuvar Sendromu (MIS-C): Olası Diğer Hastalıklar Gözden Kaçırılmamalı

Dilara Beşli Çelik¹, Gül Arga², Galip Arıcı¹, Merve Evgin¹, Fatih Bayer¹, Gülçin Bilicen¹, Ahmet Said Özal¹,
Hatice Köksal¹, Hatice Kübra Konca², Esra Çakmak Taşkın², Halil Özdemir², Ergin Çiftçi²



¹Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Ankara Üniversitesi Tıp Fakültesi, Ankara, Türkiye

²Çocuk Enfeksiyon Hastalıkları Bilim Dalı, Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Ankara Üniversitesi Tıp Fakültesi, Ankara, Türkiye



Giriş

Çocuklarda görülen COVID-19 ilişkili multisistem inflamatuvar sendromu (MIS-C) kalp, akciğer, böbrek, deri ile hematolojik, gastrointestinal ve nörolojik sistem tutulumuyla seyreden, geç başlangıçlı, ciddi bir durumdur (Tablo 1). Erken tanı ve tedavi hayatı önem taşımaktadır. Bu çalışmada MIS-C tanı kriterlerini karşılayan ancak salmonelloz tanısı alan bir vaka sunulmuş olup, MIS-C'nin bir dışlama tanısı olduğu vurgulanmıştır.

Olgu

Bilinen hastalığı olmayan 4 yaşında kız hasta döküntü, ateş, ishal ve karın ağrısı şikâyetleriyle başvurdu. Ailesinde 1 ay önce geçirilmiş COVID-19 öyküsü olan hastada COVID-PCR, COVID IgM ve IgG negatif olarak sonuçlandı. Muayenesinde alt ekstremitelerinde daha yaygın olmak üzere ekstremitelerde eritematöz plak şeklinde, basmakla solan döküntüleri görüldü (Resim 1). Batında hassasiyeti olan hastanın solunum sistemi ve kardiyovasküler sistem muayeneleri doğaldı. Laboratuvarında hemoglobin 10,6 g/dL, lökosit 17.200/mm³, nötrofil 10.600/mm³, lenfosit 5400/mm³, trombosit 472.000/mm³, CRP 159 mg/L, ESR 72 mm/sa, D-dimer 1263 ng/mL, ferritin 108,6 ng/mL, fibrinojen 7,6 g/L, LDH 326 U/L, albümin 36 g/L iken; kardiyak markerlar normal olarak sonuçlandı. Ekokardiyografide patoloji saptanmadı. Gaita mikroskopisi normaldi. COVID-19 teması olan, gastrointestinal ve cilt tutulumuna D-dimer, ESR ve CRP yüksekliği eşlik eden hastada MIS-C düşünülerek intravenöz immünglobulin (IVIG) 2 g/kg, prednizolon 2 mg/kg/gün, aspirin 3,5 mg/kg/gün ve piperasilin-tazobaktam 400 mg/kg/g tedavi başlandı. İzleminde ishal nedeniyle gönderilen gaita kültüründe *Salmonella* spp. üredi. Kan kültüründe ise üreme olmadı. Hastanın döküntüsü *Salmonella* için atipik olmakla birlikte, ishali, ateşi ve akut faz reaktanlarında yükseklik olan hastaya salmonelloz tanısı konularak MIS-C tanısı dışlandı. Mevcut tedaviler kesilerek seftriakson 100 mg/kg/gün başlandı. Hastanın takibinde ishali ve karın ağrısı düzeldi. Döküntüleri soldu. Antibiyotigi oral

Tablo 1- MIS-C Vaka Tanımı (Sağlık Bakanlığı COVID-19 Rehberi)

1. 0 - 21 yaş arası	
2. > 24 saat, > 38°C ölçülmüş ateş veya ailenin ateş varlığını bildirimi	
3. Laboratuvar tetkiklerinde inflamasyon kanıtı (En az 2 tanesi)	4. Çoklu organ sistem tutulumu (En az 2 tanesi)
- Yüksek CRP	- Kardiyovasküler (Şok, yüksek BNP veya troponin, anormal EKO, aritmi)
- Yüksek sedimentasyon	- Solunum (Pnömoni, ARDS, pulmoner emboli)
- Yüksek fibrinojen	- Böbrek (Böbrek yetmezliği)
- Yüksek prokalsitonin	- Nörolojik (Konvülsiyon, inme, aseptik menenjit)
- Yüksek D-dimer	- Hematolojik (Koagülopati, yüksek D-dimer düzeyi)
- Yüksek ferritin	- Gastrointestinal (Yüksek karaciğer enzimleri, diyare, ileus)
- Yüksek LDH	- Dermatolojik (Eritrodermi, mukozit, diğer döküntüler)
- Yüksek IL-6 seviyesi	
- Artmış nötrofil sayısı	
- Lenfositopeni	
- Hipoalbuminemi	
5. Hastaneye yatış gerektirecek ağır hastalık tablosu	
6. Alternatif başka tanı olmaması (Bakteriyel sepsis, enterovirüs enfeksiyonu gibi myokardit ilişkili enfeksiyonlar, stafillokoksis veya streptokoksis TSS)	
6. Geçirilmiş veya geçirilmekte olan SARS-CoV-2 enfeksiyonu (En az biri)	
- SARS-CoV-2 RT-PCR pozitifliği	- SARS-CoV-2 antijen pozitifliği
- SARS-CoV-2 seroloji pozitifliği	- Semptomların başlamasından önce 4 hafta içerisinde pozitif olgu teması



Resim 1. Ekstremitelerde basmakla solan eritematöz plaklar

Sonuç

COVID-19 ilişkili MIS-C olgu bildirimleri giderek artmaktadır. Mevcut tanı kriterleriyle birçok hastalığın MIS-C tanısı alması olasıdır. MIS-C'nin bir dışlama tanısı olduğu unutulmamalı, benzer tabloya neden olabilecek hastalıklar mutlaka göz önünde bulundurulmalıdır.

MIS-C

Ayırıcı Tanı

Kesişen özellikleri olan hastalıklar...

COVID-19

MIS-C

Kawasaki hastalığı



Makrofaj aktivasyon sendromu

Hemofagositik lenfohistiositoz

Toksik şok sendromu

Table 2. Differential diagnosis of MIS-C				
	MIS-C	KD	TSS	HLH/MAS
Dominantly affected age group	School-age children and adolescents	Infants and toddlers	Any age	Any age
Prolonged fever	Yes	Yes	Yes	Yes
Fissured lips	Common	Typical	Possible	Insufficient data
Nonexudative conjunctivitis	Common	Typical	Possible	Possible
Hypotension	Common	Possible	Typical	Possible
GIS symptoms	Very common	Rare	Common	Rare
Coronary aneurysms	Possible	Common	Insufficient data	Insufficient data
Heart failure	Common	Possible	Rare	Rare
Neutrophilia	Yes	Yes	Yes	No
Lymphopenia	Yes	No	No	Yes
Thrombocytopenia	Yes	No	Yes	Yes
CRP	Elevated	Elevated	Elevated	Elevated
Ferritin	Elevated	Normal, or elevated	Normal	Elevated
Hypertriglyceridemia	Common	No	No	Typical

CRP, C-reactive protein; GIS, gastrointestinal system; HLH/MAS, hemophagocytic lymphohistiocytosis/macrophage activation syndrome; KD, Kawasaki disease; MIS-C, multisystem inflammatory syndrome in children; TSS, toxic shock syndrome.





MIS-C VAKA: 24

Seroloji pozitif : 15

Covid-19 PCR (+) : 3

Klinik : 6 Bilinen Covid-19 PCR (+) ile temas: 3

GIS : 19

Mukokutanöz : 13

Solunum : 10

KVS : 9

Renal : 7

Nörolojik : 2

YBÜ yatış : 9

Tedavi:

IVIG : 23

Steroid : 24

ASA : 21

Antikoagülan : 2

Favipiravir : 1

Anakinra : 1

Tosilizumab : 0

Mortalite : 2

Acute Abdomen—A Clinical Presentation of MIS-C in Children

Emrah Gün¹ Tanıl Kendirli¹ Edin Botan¹ Berrin Demir² Ergun Ergün³ Halil Özdemir⁴
Ömer Suat Fitoz² Ergin Ciftci⁴ Ercan Tutar⁵

J Pediatr Infect Dis 2022;17:24–32.

Abstract

Objective Multisystemic inflammatory syndrome in children (MIS-C) is characterized by persistent fever, systemic hyperinflammation, and multiple-organ dysfunction. There are a few reports about MIS-C presenting with acute abdomen. The aim of this study was to demonstrate the clinical characteristics and treatment options for MIS-C-related acute abdomen and appendicitis.

Methods This was a retrospective study conducted between April 2020 and October 2020 in our pediatric intensive care unit in Turkey. Patients between the ages of 1 month and 18 years who presented with acute abdomen and were ultimately diagnosed with MIS-C were included.

Results Seven patients with a median age of 12.5 (interquartile range 10.5–13) years were enrolled. Four were females. The most frequent symptoms were fever, abdominal pain, and vomiting. Three patients had involvement of the appendix that required surgical intervention. All pathology reports were compatible with appendicitis. The other patients also had an acute abdomen. One patient had malignant hyperthermia during induction of anesthesia, so surgery was postponed and medical management was commenced. The clinical picture regressed with immunomodulation. All patients were treated with intravenous immunoglobulin and steroids. Four patients with acute abdomens improved with immunomodulation, and surgery was not needed.

Conclusion MIS-C may present with an acute abdomen. Immunomodulation should be considered instead of surgery if the clinical course is not complicated.

Keywords

- multisystem inflammatory syndrome in children
- COVID-19
- intestinal inflammation
- appendicitis
- children

Multisystem Inflammatory Syndrome in Children Admitted to a Tertiary Pediatric Intensive Care Unit

Emrah Gün¹ Tanıl Kendirli¹ Edin Botan¹ Nazmiye Türker² Anar Gurbanov¹
Burak Balaban¹ Ali Genco Gencay¹ Gül Arga³ Selen Karagözü⁴
Mehmet Gökhan Ramoğlu⁴ Halil Özdemir³ Tayfun Ucar⁴ Ercan Tutar⁴ Ergin Ciftci³

J Pediatr Intensive Care 2023;12:37–43.

Abstract

Background Multisystem inflammatory syndrome in children (MIS-C) is characterized by persistent fever, abdominal pain, vomiting, diarrhea, rash, conjunctivitis, headaches, and mucocutaneous manifestations and it can cause circulatory dysfunction, resulting in hypotension, shock, and end-organ injury in the heart and other organs and possibly death. In this study, we aimed to analyze the clinical spectrum, treatment options and outcomes of children with MIS-C who were admitted to our pediatric intensive care (PICU).

Materials and Methods Clinical and laboratory findings and treatment of the patients admitted to the PICU with MIS-C between April 2020 and January 2021 were recorded, and their outcomes were evaluated.

Results Nineteen patients with a median age of 12.5 years (interquartile range (IQR): 5.8–14.0 years) were admitted. Eleven (57.8%) were males. The most frequent clinical and laboratory features were fever (100%), abdominal pain (94.7%), rash (63.1%), headache (68.4%), diarrhea (47.3%), seizure (10.5%), cardiac dysfunction (52.6%), acute kidney injury (26.3%), lymphopenia (84.2%), and thrombocytopenia (36.8%). However, 8 patients needed mechanical respiratory support, 11 patients needed inotropes, 2 patients needed plasma exchange, and 1 patient needed continuous renal replacement therapy. All patients received corticosteroids, 17 patients (89.2%) received intravenous immunoglobulin, 2 patients received anakinra, 10 patients received acetylsalicylic acid, and 6 patients received enoxaparin. Median PICU length of stay was 3 days (IQR: 2–5) and only one patient died.

Conclusion In conclusion, MIS-C may present with a variety of clinical manifestations, and it can lead to life-threatening critical illness. Most children need intensive care and the response to immunomodulation is usually favorable.

Keywords

- multisystem inflammatory syndrome in children
- COVID-19
- children
- pediatric intensive care

COVID-19 associated multisystemic inflammatory syndrome in 614 children with and without overlap with Kawasaki disease-Turk MIS-C study group

Prof. Dr. Ergin ÇİFTÇİ
www.erginciftci.com

Dilek Yilmaz Ciftcioglu^{1,2} · Yildiz Ekemen Keles² · Benhur Sirvan Cetin³ · Nazan Dalgic Karabulut⁴ · Melike Emiroglu⁵ · Zafer Bagci⁶ · Ayse Buyukcam⁷ · Emine Hafize Erdeniz⁸ · Gul Arga⁹ · Edanur Yesil¹⁰ · Ozlem Cakici¹¹ · Adem Karbuz¹² · Zümrüt Sahbudak Bal¹³ · Soner Sertan Kara¹⁴ · Arife Ozer¹⁵ · Ozge Metin Akcan¹⁶ · Sefika Elmas Bozdemir¹⁷ · Ayse Berna Anil¹ · Hatice Uygun¹⁸ · Omer Kilic¹⁹ · Selda Hancerli Torun²⁰ · Zuhal Umit²¹ · Murat Sutcu²² · Berfin Ozgokce Ozmen²³ · Hatice Karaoglu Asrak²⁴ · Gulsum Alkan⁵ · Ahu Kara Aksay² · Cüneyt Uğur⁶ · Ahmet Ziya Birbilen⁷ · Burcu Bursal Duramaz²⁵ · Esra Akyuz Ozkan⁸ · Ozgur Burakay¹¹ · Sema Yildirim Arslan¹³ · Eda Karadag Oncel² · Serkan Fazli Celik¹⁴ · Ahmet Osman Kilic¹⁶ · Seval Ozen¹⁸ · Remzi Sarikaya¹⁵ · Demet Demirkol²⁰ · Gazi Arslan²⁴ · Ozden Turel²⁵ · Ahmet Sert⁵ · Ergul Sari²⁶ · Zerrin Orbak²⁷ · Irfan Oguz Sahin⁸ · Celal Varan¹⁸ · Hacer Akturk²⁸ · Sadiye Kubra Tuter Oz⁵ · Fatih Durak⁷ · Mehmet Burhan Oflaz¹⁶ · Manolya Kara²² · Derya Karpuz²³ · Mey Talip Petmezci¹² · Nevin Hatipoglu²⁶ · Selim Oncel¹¹ · Mehmet Turgut¹⁸ · Ferhan Elmali¹ · Ayper Somer²⁰ · Necdet Kuyucu²³ · Ener Cagri Dinleyici¹⁹ · Zafer Kurugöl¹³ · Ergin Ciftci⁹ · Ates Kara²⁹

European Journal of Pediatrics (2022) 181:2031–2043

What is New:

- *Half of the patients had clinical features that overlapped with Kawasaki disease.*
- *In patients whose clinical features overlapped with KD, procalcitonin levels were almost 15 times higher than normal.*
- *Lethargy increased the risk of overlap with KD by 2.6-fold in MIS-C patients.*
- *Transient bradycardia was noted in approximately 10% of our patients after initiation of treatment.*

Multisystem inflammatory syndrome in children associated with COVID-19 in 101 cases from Turkey (Turk-MISC study)

Dilek Yilmaz Ciftcioglu,^{1,2} Yildiz Ekemen Keles², Adem Karbuz,³ Benhur Sirvan Cetin,⁴ Sefika Elmas Bozdemir,⁵ Eda Kepenekli Kadayifci,⁶ Ozge Metin Akcan,⁷ Arife Ozer,⁸ Tugba Erat⁹, Murat Sutcu,¹⁰ Ayse Buyukcam,¹¹ Nursen Belet,¹² Emine Hafize Erdeniz,¹³ Nazan Dalgic Karabulut¹⁴, Selda Hancerli Torun,¹⁵ Selim Oncel,¹⁶ Zerrin Orbak¹⁷, Ozden Turel,¹⁸ Zeynep Gokce Gayretli Aydin,¹⁹ Omer Kilic,²⁰ Aysun Yahsi²¹, Ahi Kara Aksay,² Zeynep Ergenc,⁶ Mey Talip Petmezci,²² Mehmet Burhan Oflaz,²³ Remzi Sarikaya,²⁴ Gulcin Otari Yener,²⁵ Seval Ozen,²⁶ Doruk Gul,²⁷ Gazi Arslan,²⁸ Soner Sertan Kara,²⁹ Demet Demirkol,³⁰ Pinar Yazici Ozkaya,³¹ Yilmaz Yozgat³², Celal Varan,³³ Manolya Kara,³⁴ Gul Arga³⁵, Nurhayat Yakut,⁶ Ahmet Osman Kilic,³⁶ Ozlem Cakici,¹⁶ Mehmet Kucuk,³⁷ Ozge Kaba³⁸, Hatice Karaoglu Asrak,¹² Burcu Bursal Duramaz³⁹, Tahir Dalkiran,³⁸ Ayse Berna Anil,³⁹ Mehmet Turgut,²⁶ Bulent Karapinar,³¹ Ayper Somer,¹⁵ Ferhan Elmali,⁴⁰ Ener Cagri Dinleyici,⁴¹ Ergin Ciftci³⁵ and Ates Kara⁴²

Journal of Paediatrics and Child Health 58 (2022) 1069–1078

What is already known on this topic

- 1 Multisystem inflammatory syndrome in children (MIS-C) occurs in association with SARS-CoV-2 infection and presents with fever, involvement of multiple organ systems and evidence of inflammation.
- 2 Most patients with MIS-C are diagnosed with serological tests.
- 3 Unlike classical Kawasaki disease, most patients are over 5 years.

What this paper adds

- 1 Fever lasted at least 3 days in all patients.
- 2 Kawasaki-like features were primarily detected in children aged 5 to 12 years.
- 3 Lymphopenia was predominant over 12 years.
- 4 Some patients had bradycardia after starting treatment.

Results: The study comprised 101 patients, median age 7 years (interquartile range (IQR) 4.6–9.3); 51 (50.5%) were boys. Reverse-transcriptase polymerase chain reaction (PCR) assay was positive in 21/100 (21%) patients; 62/83 (74.6%) patients had positive serology for SARS-CoV-2. The predominant complaints were fever (100%), fatigue ($n = 90$, 89.1%), and gastrointestinal symptoms ($n = 81$, 80.2%). Serum C-reactive protein (in 101 patients, median 165 mg/L; range 112–228), erythrocyte sedimentation rate (73/84, median 53 mm/s; IQR 30–84) and procalcitonin levels (86/89, median 5 µg/L; IQR 0.58–20.2) were elevated. Thirty-eight patients (37.6%) required admission to intensive care. Kawasaki disease (KD) was diagnosed in 70 (69.3%) patients, 40 of whom had classical KD. Most patients were treated with intravenous immunoglobulin ($n = 92$, 91%) and glucocorticoids ($n = 59$, 58.4%). Seven patients (6.9%) died.



Multisystem inflammatory syndrome in children during the COVID-19 pandemic in Turkey: first report from the Eastern Mediterranean

Yasemin Ozsurekci¹ • Sibel Gürlevik¹ • Selman Kesici² • Ummusen Kaya Akca³ • Pembe Derin Oygur¹ • Kubra Aykac⁴ • Dilek Karacanoglu² • Ozlem Saritas Nakip² • Sare Ilbay¹ • Ban Katlan² • İlker Ertugrul⁵ • Ali Bülent Cengiz¹ • Ozge Basaran³ • Burcu Ceylan Cura Yayla⁴ • Jale Karakaya⁶ • Yelda Bilginer³ • Benan Bayrakci² • Mehmet Ceyhan¹ • Seza Ozen³

Received: 2 January 2021 / Revised: 31 January 2021 / Accepted: 2 February 2021

© International League of Associations for Rheumatology (ILAR) 2021, corrected publication 2021

Abstract

Objective We aimed to describe the typical clinical and laboratory features and treatment of children diagnosed with multisystem inflammatory syndrome in children (MIS-C) and to understand the differences as compared to severe/critical pediatric cases with COVID-19 in an eastern Mediterranean country.

Methods Children (aged <18 years) who diagnosed with MIS-C and severe/critical pediatric cases with COVID-19 and were admitted to hospital between March 26 and November 3, 2020 were enrolled in the study.

Results A total of 52 patients, 22 patients diagnosed with COVID-19 with severe/critical disease course and 30 patients diagnosed with MIS-C, were included in the study. Although severe COVID-19 cases and cases with MIS-C share many clinical and laboratory features, MIS-C cases had longer fever duration and higher rate of the existence of rash, conjunctival injection, peripheral edema, abdominal pain, altered mental status, and myalgia than in severe cases ($p < 0.001$ for each). Of all, 53.3% of MIS-C cases had the evidence of myocardial involvement as compared to severe cases (27.2%). Additionally, C-reactive protein (CRP) and white blood cell (WBC) are the independent predictors for the diagnosis of MIS-C, particularly in the existence of conjunctival injection and rash. Corticosteroids, intravenous immunoglobulin (IVIG), and biologic immunomodulatory treatments were mainly used in MIS-C cases rather than cases with severe disease course. There were only three deaths among 52 patients, one of whom had Burkitt lymphoma and the two cases with severe COVID-19 of late referral.

Conclusion Differences between clinical presentations, acute phase responses, organ involvements, and management strategies indicate that MIS-C might be a distinct immunopathogenic disease as compared to pediatric COVID-19. Conjunctival injection and higher CRP and low WBC count are reliable diagnostic parameters for MIS-C cases.

MIS-C Tedavi

American Academy
of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN®

Multisystem Infl

Critical Updates on COVID-19 / Clinical Guidance

What is the recommended treatment approach for MIS-C?

Clinicians who suspect MIS-C in a child should use a multidisciplinary approach involving many pediatric specialists, which may include but is not limited to cardiology, infectious disease, immunology, hematology, rheumatology, pediatric hospital medicine, and critical care, to guide individual patient treatment.

- fluid resuscitation;
- inotropic support;
- respiratory support; and
- in rare cases, extracorporeal membranous oxygenation (ECMO).

- Patients with MIS-C have been treated with IVIG, 1 to 2 grams/kg, to stabilize patient cardiac function and fluid status influence timing of IVIG therapy.
- Some patients have also been treated with steroid therapy (ranging from 2 to 30 mg/kg/day of methylprednisolone depending on severity of illness) and biologics (eg, anakinra, 2 to 10 mg/kg/day, subcutaneously or intravenously, divided every 6 to 12 hours). If the patient has laboratory or imaging evidence of myocarditis or findings concerning for coronary artery aneurysms, discussion with pediatric cardiology is suggested prior to use of steroids.
- Patients treated with steroids and/or biologics often go home with a 3-week taper of steroids and/or biologics.
- Given the need for early intervention and the need to initiate treatment for multiple possible etiologies, many patients have received concurrent antibiotic therapy.
- Assessment of clotting risk and need for treatment/prophylaxis is recommended (eg, low-dose aspirin, at a minimum, for patients with Kawasaki disease-like syndrome or enoxaparin in patients with thrombosis). Specialists involved may include cardiology and/or hematology.

MIS-C İzlem

American Academy
of Pediatrics



DEDICATED TO THE HEALTH OF ALL CHILDREN®

Multisystem Inflammatory Syndrome in Children (MIS-C) Interim Guidance

[Critical Updates on COVID-19](#) / [Clinical Guidance](#) / Multisystem Inflammatory Syndrome in Children (MIS-C) Interim Guidance

What is the recommended follow-up for MIS-C patients?

Patients diagnosed with MIS-C should have close outpatient pediatric cardiology follow-up starting 2 to 3 weeks after discharge. Patients diagnosed with myocarditis should have cardiology directed restriction and/or release for vigorous activities.

MIS-C İzlem


AMERICAN COLLEGE
of RHEUMATOLOGY
Empowering Rheumatology Professionals

Cardiac management of MIS-C:

- Patients with MIS-C and abnormal BNP and/or troponin T at diagnosis should have these laboratory parameters trended over time until they normalize (H).
- EKGs should be performed at a minimum of every 48 hours in MIS-C patients who are hospitalized and during follow-up visits. If conduction abnormalities are present, patients should be placed on continuous telemetry while in the hospital, and Holter monitors should be considered during follow-up (M/H).
- Echocardiograms conducted at diagnosis and during clinical follow-up should include evaluation of ventricular/valvar function, pericardial effusion, and coronary artery dimensions with measurements indexed to body surface area using z-scores (H).
- Echocardiograms should be repeated at a minimum of 7-14 days and 4-6 weeks after presentation. For those patients with cardiac abnormalities occurring in the acute phase of their illness, an echocardiogram 1 year after MIS-C diagnosis could be considered. Patients with left ventricular (LV) dysfunction and/or CAA will require more frequent echocardiograms (M/H).
- Cardiac MRI may be indicated 2-6 months after MIS-C diagnosis in patients who presented with significant transient LV dysfunction in the acute phase of illness (LV ejection fraction <50%) or persistent LV dysfunction. Cardiac MRI should focus on myocardial characterization including functional assessment, T1/T2 weighted imaging, T1 mapping and extracellular volume (ECV) quantification, and late gadolinium enhancement (H).
- Cardiac CT should be performed in patients with suspicion of distal CAAs that are not well seen on echocardiogram (M).

MIS-C

Tam Olarak Nedir?



MIS-C


Tam Olarak Nedir?



Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management

Morbidity and Mortality Weekly Report

Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection — United Kingdom and United States, March–August 2020



MIS-C

Buzdağının Altında Neler Var?



Jolyon Attwooll

10 Jun 2022

‘Significant’ drop in MIS-C risk under Omicron: study

Vaccination also looks to be confirmed as a factor in reducing the risk of complications in children after COVID-19 infection, according to new research.



There have been more than 100 cases of MIS-C in Australia so far.

Omicron causes far fewer cases of multisystem inflammatory syndrome in children (MIS-C), a new study from Denmark suggests.



